Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google (GOOGL) executive.

Isomorphic was spun out of Google’s AI research arm Google DeepMind in 2021, but remains a wholly owned subsidiary of its parent company, Alphabet. The start-up’s potential has attracted big pharmaceutical partners, which are keen to lower expenses and boost efficiency of the costly drug development process.

Major tech company's new AI algorithm can predict the weather with incredible accuracy — here's why it won't replace forecasters first appeared on The Cool Down.

AI creatives with access to Google’s Veo 2 text-to-video tool say it’s another “leap forward” for video generation Veo 2 improves on image quality, realistic motion and physics and adhering closely to even complex text prompts Still,

The order, signed in October 2023, required companies building powerful AI systems to share their safety test results with the federal government and come up with ways to limit their models’ biases and discrimination.

Google DeepMind spinoff Isomorphic Labs expects testing on its first AI-designed drugs to begin this year, as tech startups race to turn algorithmic magic into actual treatments. “We’ll hopefully have

The CEO of Google Mind has suggested clinical trials of the first drugs designed with the help of AI could begin this year.

The company fulfilled requests from Israel’s military for more access to AI tools as it sought to compete with Amazon, documents obtained by The Post show.

With "Mind Evolution" LLMs can use search and genetic algorithms to generate and combine different solutions and find the optimal one.

Demis Hassabis is the CEO of Google DeepMind. Demis thinks new agent type systems will be able to perform additional tree of knowledge search to achieve

Mistral, the French AI lab, is working toward an initial public offering, co-founder and CEO Arthur Mensch said in an interview at Davos.

Business Insider's diary takes you behind the scenes on day three of the World Economic Forum in Davos.